Publication | Open Access
LBA31 Neoadjuvant nivolumab plus relatlimab (anti-LAG3) in locally advanced MMR-deficient colon cancers: The NICHE-3 study
24
Citations
0
References
2023
Year
Gastrointestinal OncologyNiche-3 StudyMedicineImmunologyColorectal CancerPathologyImmune Checkpoint InhibitorOncologyLba31 Neoadjuvant
No additional data available for this publication yet. Check back later!